Celgene Corp. has completed its acquisition of Receptos, Inc. for approximately $7.2 billion. The acquisition expands Celgene’s Inflammation & Immunology portfolio, adding Ozanimod, an oral, selective sphingosine 1-phosphate 1 and 5 receptor modulator (S1P) to its pipeline of potential disease-altering medicines and investigational compounds.
 
Clinical studies of Ozanimod have demonstrated several areas of potential advantage over existing oral therapies for the treatment of ulcerative colitis (UC) and relapsing multiple sclerosis (RMS), including its cardiac, hepatotoxicity and lymphocyte recovery profile. Phase III trials in UC and RMS are ongoing and data are expected in 2017-18. Ozanimod is also positioned to potentially become the first S1P receptor modulator to be approved for IBD.
 
“The Receptos acquisition provides a transformational opportunity for Celgene to impact multiple therapeutic areas,” said Bob Hugin, chairman and chief executive officer of Celgene. “This acquisition enhances our I&I portfolio and allows us to leverage the investments made in our global organization to accelerate our growth in the medium and long-term.”